United Health Group, Inc.'s inhouse pharmacy benefit manager (PBM) Optum Rx plans to include up to three biosimilar versions of AbbVie Inc.'s Humira (adalimumab) on its formularies in 2023, beginning with the first one that becomes available. The PBM is one of the first big players to outline its strategy for incorporating biosimilar versions of Humira on formularies, which will play an important role in how quickly the brand market share erodes and how quickly biosimilars gain traction.
"The availability of Humira biosimilars is one of the biggest opportunities in years to lower costs and increase accessibility for consumers who need expensive specialty